Patents by Inventor James Andrew Whitney

James Andrew Whitney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC IL-10/CARRIER CONSTRUCTS FOR TREATMENT OF POUCHITIS AND METHODS OF USE
    Publication number: 20250235506
    Abstract: Described herein are methods for treating pouchitis by orally administering a cholix-IL-fusion protein. Corresponding oral formulations and the effects resulting from administration of such oral formulations are disclosed.
    Type: Application
    Filed: October 3, 2024
    Publication date: July 24, 2025
    Inventors: Bittoo Kanwar, James Andrew Whitney, Kyler Lugo, Emily Weng, Drew Hotson
  • Treatment of ACVR1-mediated diseases
    Patent number: 10245268
    Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: April 2, 2019
    Assignee: Sierra Oncology, Inc.
    Inventors: Brian Koh, Igor Theurl, Matthew Robert Warr, James Andrew Whitney
  • TREATMENT OF ACVR1-MEDIATED DISEASES
    Publication number: 20180042933
    Abstract: Provided herein are methods, compositions, and kits for treating ACVR-1-mediated diseases using N-(cyanomethyl)-4-[2-4-morpholinoanilino)pyrimidin-4-yl]benzamide.
    Type: Application
    Filed: August 8, 2017
    Publication date: February 15, 2018
    Inventors: Brian Koh, Igor Theurl, Matthew Robert Warr, James Andrew Whitney
  • (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: 9809559
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 7, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
    Publication number: 20160347719
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Application
    Filed: August 8, 2016
    Publication date: December 1, 2016
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: 9469613
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: October 18, 2016
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS
    Publication number: 20160279135
    Abstract: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Inventors: Brian Lannutti, Sarah Meadows, Christophe Queva, Matthew Robert Warr, James Andrew Whitney
  • (N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOPHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
    Publication number: 20150361050
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Application
    Filed: June 11, 2015
    Publication date: December 17, 2015
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS
    Publication number: 20150148345
    Abstract: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Brian Lannutti, Sarah Meadows, Christophe Queva, Matthew Robert Warr, James Andrew Whitney
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE48285
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 27, 2020
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE49445
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 7, 2023
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE50497
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: July 22, 2025
    Assignee: GlaxoSmithKline LLC
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin